טוען...
Preclinical Pharmacokinetics and Biodistribution Studies of (89)Zr-Labeled Pembrolizumab
Pembrolizumab is a humanized monoclonal antibody targeting programmed cell death protein 1 (PD-1) found on T and pro-B cells. Pembrolizumab prevents PD-1 ligation by both PD-L1 and PD-L2, preventing the immune dysregulation that otherwise occurs when T-cells encounter cells expressing these ligands....
שמור ב:
| הוצא לאור ב: | J Nucl Med |
|---|---|
| Main Authors: | , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Society of Nuclear Medicine
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5209640/ https://ncbi.nlm.nih.gov/pubmed/27493273 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2967/jnumed.116.177857 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|